Replies to post #2715 on Sarepta Therapeutics (SRPT)

[badbadbad]

SRPT / CNBC

http://www.cnbc.com/2016/09/19/sarepta-therapeutics-shares-briefly-leap-80-after-fda-approves-eteplirsen-drug.html

[legalizeMJ]

Link:SRPT drug get approved, price target=$88.per share.

https://www.thestreet.com/story/13744847/1/sarepta-srpt-stock-upgraded-on-dmd-drug-approval.html?puc=TSMKTWATCH&cm_ven=TSMKTWATCH

Additionally, William Blair analysts noted that Sarepta should "move into a hyper-growth phase" of profit generation as there is currently no competition in the DMD drug market.

William Blair upgraded the stock to "outperform" from "market perform" and set its price target at $88.

Within 2 weeks from today, SRPT stock will be above $188.(one hundred eighty eight dollars) per share on short squeezes because SRPT is a heavily shorted stock.

SRPT is a strong BUY.